<track id="tnf1n"><strike id="tnf1n"></strike></track>
  • <table id="tnf1n"></table>
    <p id="tnf1n"><strong id="tnf1n"><xmp id="tnf1n"></xmp></strong></p>
  • <big id="tnf1n"><span id="tnf1n"></span></big>

  • <pre id="tnf1n"><label id="tnf1n"></label></pre>
    豪森藥業
    • Overview
    • 1995 Initial establishment
      A principal subsidiary of Hansoh Pharma (03692.HK)
      7
      Launched innovative drugs
      Top 100
      Pharmaceutical companies worldwide
      Top 3
      China's best Industrial enterprises in pharmaceutical R&D pipeline

    Therapy Areas

    • Anti-tumor
      Anti-tumor
      Anti-tumor
      Anti-tumor
      Anti-tumor
      Anti-tumor
      We focus on the develoment of new drugs in the field of common and hostile cancers.Our innovative medicine programs in clinical trials include HS-20106 injection, HS-20105 injection, HS-20117 injection, HS-10516 capsules, HS-10382 tablets, HS-10370 tablets, HS-10502 tablets, HS-10365 capsules, HS-20089 injection, HS-20093 injection, HS-10352 tablets, HS-10241 tablets, etc.
      More +
    • Anti-infectives
      Anti-infectives
      Anti-infectives
      Anti-infectives
      Anti-infectives
      Anti-infectives
      We focus on the development of new drugs in the fields of antiviral, anti-complex bacterial infection and anti-fungal infection. Our innovative medicine programs in clinical trials includeCitric Acid Erythorbate tablets, etc.
      More +
    • CNS Diseases
      CNS Diseases
      CNS Diseases
      CNS Diseases
      CNS Diseases
      CNS Diseases
      We focus on the development of new drugs in the fields of psychiatric and neurological disorders.Our innovative medicine programs in clinical trials include HS-10380 tablets, HS-10506 tablets, HS-10353 capsules, HS-10509 tablets, etc.
      More +
    • Metabolic Diseases
      Metabolic Diseases
      Metabolic Diseases
      Metabolic Diseases
      Metabolic Diseases
      Metabolic Diseases
      We focus on the development of new drugs in the field of metabolic diseases such as diabetes and obesity. Our innovative medicine programs in clinical trials include HS-10511 tablets, HS-20094 injection, HS-10384 tablets, HS-10518 capsules, HS-10390 tablets, HS-10501 tablets, and HS-10398 capsules, etc.
      More +
    • Autoimmune Diseases
      Autoimmune Diseases
      Autoimmune Diseases
      Autoimmune Diseases
      Autoimmune Diseases
      Autoimmune Diseases
      We focus on the development of new drugs in the field of autoimmune diseases. Our innovative medicine programs in clinical trials includeHS-10374 tablets etc.
      More +
    R&D
    Innovation
    Jiangsu Hansoh Pharma Research Institute
    Jiangsu Hansoh Pharma Research Institute
    More
    Jiangsu Hansoh Pharma Administrative R&D Center
    Jiangsu Hansoh Pharma Administrative R&D Center
    More
    • Substantial investment on R&D
      In 2023, R&D investments increased by 23.8% year-on-year, accounting for 20.8% of the revenue
    • Competitive R&D pipeline
      Over 50 clinical studies for 30 innovative drugs at different clinical development stages.
    • Highly efficient capability to discover innovative drugs
      The R&D pipeline covers peptides , small molecules, biologics, ADC drugs, siRNAs, and more.
    A broader world, let's discover together
    Join Hansoh Pharma +
    Work with us
    We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
    Join Hansoh Pharma +
    国产自愉怕一区二区|久久er99热精品一区二区|精品韩国三级在线观看视频|亚洲va久久久噜噜噜久久男同
    <track id="tnf1n"><strike id="tnf1n"></strike></track>
  • <table id="tnf1n"></table>
    <p id="tnf1n"><strong id="tnf1n"><xmp id="tnf1n"></xmp></strong></p>
  • <big id="tnf1n"><span id="tnf1n"></span></big>

  • <pre id="tnf1n"><label id="tnf1n"></label></pre>